CVD and obesity in transitional Syria: a perspective from the Middle East [0.03%]
中东视角:过渡期叙利亚的CVDRM和肥胖问题
Hani Barakat,Hanniya Barakat,Mohamad K Baaj
Hani Barakat
Purpose: Syria is caught in the middle of a disruptive nutritional transition. Its healthcare system is distracted by challenges and successes in other areas while neglecting to address the onslaught of Syria's cardiovasc...
Differential pharmacology and benefit/risk of azilsartan compared to other sartans [0.03%]
阿利沙坦与其他沙坦类药物的药理学差异和疗效/风险比
Theodore W Kurtz,Takashi Kajiya
Theodore W Kurtz
Azilsartan, an angiotensin II type 1 (AT(1)) receptor blocker (ARB), was recently approved by regulatory authorities for treatment of hypertension and is the 8th ARB to join the clinical market. This article discusses the medical reasons fo...
Nieves Gonzalo,Carlos Macaya
Nieves Gonzalo
Coronary stents have improved very significantly the immediate and long-term results of percutaneous coronary interventions. However, once the vessel has healed, the scaffolding function of the stent is no longer needed, and the presence of...
Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty [0.03%]
HORIZONS-AMI研究结果:比伐卢定可改善急性ST段抬高心肌梗死患者行经皮冠状动脉介入术后的长期存活率
Ashish Shah,Dmitriy N Feldman
Ashish Shah
Cardiovascular disease is the leading cause of death in the US. For patients with ST-elevation myocardial infarction (STEMI), urgent reperfusion of the culprit arterial occlusion, often achieved via primary percutaneous coronary interventio...
Jane Hoover-Plow,Yanqing Gong
Jane Hoover-Plow
Cardiovascular diseases (CVDs) are the leading cause of death worldwide. The use of stem cells to improve recovery of the injured heart after myocardial infarction (MI) is an important emerging therapeutic strategy. However, recent reviews ...
Beatriz Jáuregui-Garrido,Ignacio Jáuregui-Lobera
Beatriz Jáuregui-Garrido
Eating disorders are usually associated with an increased risk of premature death with a wide range of rates and causes of mortality. "Sudden death" has been defined as the abrupt and unexpected occurrence of fatality for which no satisfact...
Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options [0.03%]
动脉血栓疾病的口服抗血小板治疗:现有及新兴药物概述
Dan J Fintel
Dan J Fintel
Clinical presentations of atherothrombotic vascular disease, such as acute coronary syndromes, ischemic stroke or transient ischemic attack, and symptomatic peripheral arterial disease, are major causes of morbidity and mortality worldwide....
Evolving role of platelet function testing in coronary artery interventions [0.03%]
血小板功能检测在冠状动脉介入治疗中的应用及其作用的演变
Rakesh K Sharma,Donald J Voelker,Rohit Sharma et al.
Rakesh K Sharma et al.
The substantial reduction in ischemic events provided by the dual antiplatelet regimen with aspirin and clopidogrel is well documented in patients with acute coronary syndrome and patients undergoing percutaneous coronary intervention. Rece...
Aldo Innocente Galeandro,Giovanni Quistelli,Pietro Scicchitano et al.
Aldo Innocente Galeandro et al.
Background: The study aim was to test the accuracy (intra and interobserver variability), sensitivity, and specificity of a simplified noninvasive ultrasound methodology for mapping superficial and deep veins of the lower...
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders [0.03%]
新型抗凝药物:以口服直接凝血酶抑制剂达比加群酯预防和治疗静脉及动脉血栓形成性疾病的作用为重点的研究进展
Ola E Dahl
Ola E Dahl
Venous thromboembolism, presenting as deep vein thrombosis or pulmonary embolism, is a major challenge for health care systems. It is the third most common vascular disease after coronary heart disease and stroke, and many hospitalized pati...